A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
Price : $35 *
At a glance
- Drugs AZD 5213 (Primary) ; Pregabalin
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jan 2015 Planned number of patients changed from 60 to 46 as reported by ClinicalTrials.gov.
- 12 Jan 2015 Planned End Date changed from 1 Jun 2014 to 1 May 2015 as reported by ClinicalTrials.gov.